Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs

Gastroenterology

Volumn 154, Issue 3, 2018, Pages 500-514

  Bjarnason, Ingvar ^a   Scarpignato, Carmelo ^b   Holmgren, Erik ^a   Olszewski, Michael ^a   Rainsford, Kim D ^c   Lanas, Angel ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PARMA   (Italy)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Bacteria; Bile Acids; Drug Induced Intestinal Damage; GI; Prostaglandin

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; PHOSPHOLIPID; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

BILIARY EXCRETION; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; HUMAN; MUCUS SECRETION; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; STOMACH ACID SECRETION; STOMACH DISEASE; TISSUE REACTION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECT; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; MITOCHONDRION; PATHOGENICITY; PATHOLOGY;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; HUMANS; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PHOSPHOLIPIDS; PROSTAGLANDINS;

EID: 85044317033     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.10.049     Document Type: Review

References (154)

1. Singh, G., Triadafilopoulos, G., Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 56:Suppl (1999), 18–24.
2. Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
3. Nissen, S.E., Yeomans, N.D., Solomon, D.H., et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375 (2016), 2519–2529.
4. Bjarnason, I., Scarpignato, C., Takeuchi, K., et al. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 26 (2007), 95–106.
5. Geis, G.S., Stead, H., Wallemark, C.B., et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl 28 (1999), 11–14.
6. Bjarnason, I., Hayllar, J., Macpherson, A.J., et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 104 (1993), 1832–1847.
7. Maiden, L., Thjodleifsson, B., Theodors, A., et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology, 128, 2005 1172−118.
8. Vane, J.R., Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature 231 (1971), 232–235.
9. Whittle, B.J., Arachidonic acid metabolites and the gastro-intestinal toxicity of anti-inflammatory agents. Prostaglandins 21:Suppl (1981), 113–118.
10. Vane, J.R., Towards a better aspirin. Nature 367 (1994), 215–216.
11. Whittle, B.J.R., Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80 (1981), 94–98.
12. Peskar, B.M., On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. Biochem Biophys Acta 487 (1977), 307–314.
13. Strub, K.M., Muller, R.K., Relation between ulcerogenic activity of various NSAID and their potency as inhibitors of prostaglandin synthesis in vivo. Agents Actions 4:Suppl (1979), 245–254.
14. Graham, D.Y., Agrawal, N.M., Roth, S.H., Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter double blind, placebo-controlled trial. Lancet, 1988 ii:1277−1280.
15. Silverstein, F.E., Graham, G.Y., Senior, J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatoy drugs. Ann Int Med 123 (1995), 241–249.
16. Roberts, A., Cytoprotection by prostaglandins. Gastroenterology 77 (1975), 761–767.
17. Jiranek, G.C., Kimmey, M.B., Saunders, D.R., et al. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology 96 (1989), 656–661.
18. Bardhan, K.D., Bjarnason, I., Scott, D.L., et al. The prevention and healing of acute NSAID-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 32 (1993), 990–995.
19. Laine, L., Takeuchi, K., Tarnawski, A., Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 165 (2008), 41–60.
20. Rostom, A., Muir, K., Dubé, C.J., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5 (2007), 818–828.
21. Wallace, J.L., Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol Rev 88 (2008), 1547–1565.
22. Whittle, B.J.R., Unwanted effects of aspirin and related agents on the gastrointestinal tract. Vane, J.R., Botting, R.M., (eds.) Aspirin and other Salicylates, 1992, Chapman & Hall Medical, London, 465–509.
23. Whittle, B.J.R., Mechanism underlying gastric mucosal damage induced by indomethacin and bile salt, and the actions of prostaglandins. Br J Pharmacol 60 (1977), 455–460.
24. Whittle, B.J.R., Protective mechanisms of the gastric mucosa. Gustsavsson, S., Kumar, D., Graham, D.Y., (eds.) The Stomach, 1992, Churchill Livingstone, Edinburgh, 81–101.
25. Wallace, J.L., Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112 (1997), 1000–1016.
26. Wallace, J.L., McKnight, G.W., The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal anti-inflammatory drugs and endothelin. Gastroenterology 99 (1990), 295–304.
27. Wallace, J.L., Caliendo, G., Santagada, V., et al. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 132 (2007), 261–271.
28. Asako, H., Kubes, P., Wallace, J., et al. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 103 (1992), 146–152.
29. McCafferty, D.M., Granger, D.N., Wallace, J.L., Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rat. Gastroenterology 109 (1995), 1173–1180.
30. 2 induces ulceration of gastric mucosa. Nature 292 (1981), 472–474.
31. Wallace, J.L., The 1994 Merk Frosst Award. Mechanism of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 72 (1994), 1493–1498.
32. Syer, S.D., Blackler, R.W., Martin, R., et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol 50 (2015), 387–393.
33. Ligumski, M., Golanska, E.M., Hansen, D.G., et al. Aspirin can inhibit gastric mucosal cyclo-oxigenase without causing lesions in the rat. Gastroenterology 84 (1983), 756–761.
34. Ligumski, M., Sestieri, M., Karmeli, F., et al. Rectal administration of nonsteroidal antiinflammatory drugs. Gastroenterology 98 (1990), 1245–1249.
35. Langenbach, R., Morham, S.G., Tiano, H.F., et al. Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83 (1995), 483–492.
36. Sigthorsson, G., Simpson, R.J., Walley, M., et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122 (2002), 1913–1923.
37. Wallace, J.L., McKnight, W., Reuter, B.K., et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000), 706–714.
38. Takeuchi, K., Smale, S., Premchand, P., et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4 (2006), 196–202.
39. Morham, S.G., Langenbach, R., Loftin, C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995), 473–482.
40. Sigthorsson, G., Crane, R., Simon, T., et al. COX-2 specific inhibition with rofecoxib 25 or 50 mg OD does not increase intestinal permeability: a controlled study with placebo and indomethacin 50 mg TID. Gut 47 (2000), 527–532.
41. Maiden, L., Thjodleifsson, B., Seigal, A., et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 5 (2007), 1040–1045.
42. Somasundaram, S., Hayllar, J., Rafi, S., et al. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 30 (1995), 289–299.
43. Bjarnason, I., Takeuchi, K., Bjarnason, A., et al. The G.U.T. of gut. Scand J Gastroenterol 39 (2004), 807–815.
44. Brune, K., Glatt, M., Graf, P., Mechanisms of action of anti-inflammatory drugs. Gen Pharmacol 7 (1976), 27–33.
45. Brune, K., Graf, P., Rainsford, K.D., Biodistribution of acidic anti-inflammatory drugs: a clue to the understanding of their effects and side-effects. Drug Exp Clin Res 2 (1977), 155–168.
46. Rainsford, K.D., Structure-activity relationships of non-steroidal anti-inflammatory drugs. I. Gastric ulcerogenic activity. Agents Actions 8 (1978), 587–605.
47. Rainsford, K.D., Whitehouse, M.W., Anti-inflammatory antipyretic salicylic acid esters, with low gastric ulcerogenic activity. Agents Actions 10 (1980), 451–456.
48. Varum, F.J., Veiga, F., Sousa, J.S., et al. An investigation into the role of mucus thickness on mucoadhesion in the gastrointestinal tract of pig. Eur J Pharm Sci 40 (2010), 335–341.
49. Lichtenberger, L.M., Wang, Z.-M., Romero, J.J., et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1 (1995), 154–158.
50. Lichtenberger, L.M., The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 57 (1995), 565–583.
51. Goddard, P.J., Hills, B.A., Lichtenberger, L.M., Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?. Am J Physiol 252 (1987), G421–G430.
52. Lugea, A., Antolin, M., Mourelle, M., et al. Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Gastroenterology 112 (1997), 1931–1939.
53. Lichtenberger, L.M., Zhou, Y., Jayaraman, V., et al. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine. Biochem Biophys acta 182 (2012), 994–1002.
54. Lichtenberger, L.M., Ulloa, C., Romero, J.J., et al. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology 111 (1996), 990–995.
55. Lim, Y.J., Phan, T.M., Dial, E.J., et al. In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion 86 (2012), 171–177.
56. Lichtenberger, L.M., Romero, J.J., Dial, E.J., Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 150 (2007), 913–919.
57. Anand, B.S., Romero, J.J., Sanduja, S.K., et al. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94 (1999), 1818–1822.
58. Cryer, B., Bhatt, D.L., Lanza, F.L., et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 106 (2011), 272–277.
59. Lanza, F.L., Marathi, U.K., Anand, B.S., et al. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther 28 (2008), 431–442.
60. Tyler, D.D., Respiratory enzyme systems of mitochondria. Tyler, D.D., (eds.) The Mitochondrian in Health and Disease, 1992, VCH Publishers, New York, 270–351.
61. Zamzami, N., Susin, S.A., Marchetti, P., et al. Mitochondrial control of nuclear apoptosis. J Exp Med 183 (1996), 1533–1544.
62. Sivalingam, N., Basivireddy, J., Balasubramanian, K.A., et al. Curcumin attenuates indomethacin-induced oxidative stress and mitochondrial dysfunction. Arch Toxicol 82 (2008), 471–481.
63. Madara, J.L., Tight junction dynamics: is paracellular transport regulated?. Cell 53 (1988), 497–498.
64. Masubuchi, Y., Saito, H., Horie, T., Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J Pharmacol Exp Ther 287 (1998), 208–213.
65. Adams, S.S., Cobb, R., A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs. Nature 181 (1958), 773–774.
66. Adams, S.S., Cliffe, E.E., Lessel, B., et al. Some biological properties of ‘ibufenac', a new anti-rheumatic drug. Nature 200 (1963), 271–272.
67. Glarborg-Jorgensen, T., Weis-Fogh, U.S., Neilsen, H.H., et al. Salicylate- and aspirin-induced uncoupling of oxidative phosphorylation in mitochondria isolated from the mucosal membrane of the stomach. Scand J Lab Invest 36 (1976), 649–653.
68. Spenny, J.G., Bhown, M., Effect of prostaglandin acid on gastric mucosa II. Mucosal ATP and phosphocreatinine content and salicylic effects on mitochondrial metabolism. Gastroenterology 73 (1977), 995–999.
69. Somasundaram, S., Rafi, S., Hayllar, J., et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID-induced injury to the rat intestine. Gut 41 (1997), 344–353.
70. Mahmud, T., Rafi, S.S., Scott, D.L., et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arth Rheum 39 (1996), 1998–2003.
71. Roth, S.H., Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 83 (1987), 25–30.
72. Basivireddy, J., Vasudevan, A., Jacob, M., et al. Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes. Biochem Pharmacol 64 (2002), 339–349.
73. Mahmud, T., Somasundaram, S., Sigthorsson, G., et al. Enantiomers of flurbiprofen can distingush key pathophysiological steps of NSAID-enteropathy in the rat by steroselective inhibition of cyclooxygenase. Gut 43 (1998), 775–782.
74. Somasundaram, S., Macpherson, A.J., Hayllar, J., et al. Enterocyte mitochondrial damage due to NSAID in the rat. Gut, 33(Suppl 1), 1992, S5.
75. Somasundaram, S., Rafi, S., Jacob, M., et al. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 40 (1997), 608–613.
76. Krause, M.M., Brand, M.D., Krauss, S., et al. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum 48 (2003), 1438–1444.
77. Fornai, M., Antonioli, L., Colucci, R., et al. NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?. J Pharmacol Exp Ther 348 (2014), 86–95.
78. Sigthorsson, G., Jacob, M., Wrigglesworth, J.M., et al. A comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiological steps in the pathogenesis of nsaid enteropathy in the rat. Scand J Gastroenterol 33 (1998), 728–735.
79. Tibble, J.A., Sigthorsson, G., Foster, R., et al. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 35 (2000), 802–807.
80. Kawai, K., Shiojiri, H.S., Fukushima, H., et al. The inhibition of mitochondrial respiration by indomethacin, a non-steroidal anti-inflammatory agent possessing inhibitory effect on prostaglandin biosynthesis. Res Commun Chem Path Pharmacol 48 (1984), 267–274.
81. McDougall, Markham, A., Cameron, I., et al. The mechanism of inhibition of mitochondrial oxidative phosphorylation by the non-steroidal anti-inflammatory agent diflunisal. Biochem Pharmacol 32 (1983), 2595–2598.
82. Mehlman, M.A., Tobin, R.B., Sporn, E.M., Oxidative phosphorylation and respiration by rat liver mitochondria from aspirin treated rats. Biochem Pharmacol 21 (1972), 3279–3285.
83. Tokumitsu, Y., Lee, S., Ui, M., In vitro effects of nonsteroidal antiinflammatory drugs on oxidative phosphorylation in rat liver mitochondria. Biochem Pharmacol 26 (1977), 2101–2106.
84. 2 synthase-1. Nature 367 (1994), 243–249.
85. Kurumbail, R.G., Stevens, A.M., Gierse, J.K., et al. Structural basis for selective inhibition of cycoloxygenase-2 by anti-inflammatory agents. Nature 384 (1996), 644–648.
86. Vane, J.R., Botting, R.M., Formation and actions of prostaglandins and their inhibition of their synthesis. Vane, J.R., Botting, R.M., (eds.) Therapeutic Roles of Selective COX-2 Inhibitors, 2001, William Harvey Press, Burlington Press, Foxton, Cambridge, UK, 1–47.
87. Kurumbail, R.G., Kiefer, J.R., Marnett, L.J., Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 11 (2001), 752–760.
88. Papapetropoulos, A., Foresti, R., Ferdinandy, P., Pharmacology of the ‘gasotransmitters' NO, CO and H2S: translational opportunities. Br J Pharmacol 172 (2015), 1395–1396.
89. Martín, M.J., Jiménez, M.D., Motilva, V., New issues about nitric oxide and its effects on the gastrointestinal tract. Curr Pharm Dis 7 (2001), 881–908.
90. Jansson, E.A., Petersson, J., Reinders, C., et al. Protection from nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers by dietary nitrate. Free Radic Biol Med 42 (2007), 510–518.
91. Lanas, A., Bajador, E., Serrano, P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000), 834–839.
92. Fiorucci, S., Antonelli, E., Distrutti, E., et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 129 (2005), 1210–1220.
93. Wallace, J.L., Caliendo, G., Santagada, V., et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 159 (2010), 1236–1246.
94. Miura, S., Suematsu, M., Tanaka, S., et al. Microcirculatory disturbance in indomethacin-induced intestinal ulcer. Am J Physiol 26 (1991), G213–G219.
95. Davies, N.M., Roseth, A.G., Appleyard, C.B., et al. NO-naproxen versus naproxen: Ulcerogenic, analgesic and anti-inflammatory effect. Aliment Pharmacol Ther 11 (1997), 69–79.
96. Fiorucci, S., Santucci, L., Gresele, P., et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124 (2003), 600–607.
97. Hawkey, C.J., Jones, J.I., Atherton, C.T., et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52 (2003), 1537–1542.
98. Lohmander, L.S., McKeith, D., Svensson, O., et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64 (2005), 449–456.
99. Wallace, J.L., Elliott, S.N., Del Soldato, P., et al. Gastrointestinal-sparing anti-inflammatory drugs: the development of nitric oxide-releasing NSAIDs. Drug DR 42 (1997), 144–149.
100. Zanardo, R.C., Brancaleone, V., Distrutti, E., et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20 (2006), 2118–2120.
101. Anthony, A., Dhillon, A.P., Nygard, G., et al. Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther 7 (1993), 29–40.
102. Anthony, A., Pounder, R.E., Dhillon, A.P., et al. Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 41 (1997), 763–770.
103. Kelly, D., Piasecki, C., Anthony, A., et al. Early indomethacin lesions in rat jejunum: reduced focal blood flow and shortening of villi preceed ulceration. Gut 42 (1998), 366–373.
104. Nygard, G., Anthony, A., Piasecki, C., et al. Acute indomethacin-induced jejunal injury in the rat: Early morphological and biochemical changes. Gastroenterology 106 (1994), 567–575.
105. Weiss, G.J., Tissue destruction by neutrophils. N Engl J Med 320 (1989), 365–376.
106. Wilkinson, P.C., Leucocyte locomotion: determinants of locomotor capacity, chemotaxis and chemokinesis. Peters, T.J., (eds.) The Cell Biology of Inflammation in the Gastrointestinal Tract, 1990, Corners Publication, Hull, UK, 15–27.
107. Scheiman, J.M., Yeomans, N.D., Talley, N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006), 701–710.
108. Yeomans, N.D., Tulassay, Z., Juhász, L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998), 719–726.
109. Taha, A.S., HN, Hawkey, C.J., Swannell, A.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334 (1996), 1435–1439.
110. Quinn, C.M., Bjarnason, I., Price, A.B., Gastritis in patients on non-steroidal anti-inflammatory drugs. Histopathology 23 (1993), 341–348.
111. Konturek, J.W., Dembinski, A., Konturek, S.J., et al. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 114 (1998), 245–255.
112. White, J.R., Winter, J.A., Robinson, K., Differential inflammatory response to Helicobacter pylori infection: etiology and clinical outcomes. J Inflamm Res 8 (2015), 137–147.
113. Datta De, D., Roychoudhury, S., To be or not to be: the host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J Gastroenterol 21 (2015), 2883–2895.
114. Lanas, A., Chan, F.K., Peptic ulcer disease. Lancet 390:10094 (2017), 613–624.
115. Iijima, K., Ara, N., Abe, Y., et al. Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level. J Gastroenterol 47 (2012), 1291–1297.
116. Huang, J.Q., Sridhar, S., Hunt, R.H., Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002), 14–22.
117. Duggan, D.E., Hooke, K.F., Noll, R.M., et al. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 25 (1975), 1749–1754.
118. Beck, W.S., Schneider, H.T., Dietzel, K., et al. Gastrointestinal ulcerations induced by anti-inlammatory drugs in rats: physicochemical and biochemical factors involved. Arch Toxicol 64 (1990), 210–216.
119. Wax, J., Clinger, W.A., Varner, P., et al. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 58 (1970), 772–780.
120. Brodie, D.A., Cook, P.G., Bauer, B.J., et al. Indomethacin-induced intestinal lesions in the rat. Toxicol Appl Pharmacol 17 (1970), 615–624.
121. Melrange, R., Gentry, C., O'Connell, C., et al. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-6-naphthylacetic acid (6MNA). Digest Dis Sci 37 (1992), 1847–1852.
122. Semple, P.F., Russell, R.I., Role of bile acids in the pathogenesis of aspirin-induced gastric mucosal hemorrhage in rats. Gastroenterology 68 (1975), 67–70.
123. Zhou, Y., Dial, E.J., Doyen, R., et al. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 298 (2010), G722–G731.
124. Barrios, J.M., Lichtenberger, L.M., Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats. Gastroenterology 118 (2000), 1179–1186.
125. Dial, E.J., Darling, R.L., Lichtenberger, L.M., Importance of biliary excretion of indomethacin in gas-trointestinal and hepatic injury. Gastroenterol Hepatol 23 (2008), 384–389.
126. Distrutti, E., Santucci, L., Cipriani, S., et al. Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa. J Gastroenterol 50 (2015), 707–719.
127. Pavlidis, P., Powell, N., Vincent, R.P., et al. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?. Aliment Pharmacol Ther 42 (2015), 802–817.
128. Uchida, A., Yamada, T., Hayakawa, T., et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol 272 (1997), G1249–G1257.
129. Lloyd-Still, J.D., Beno, D.W., Uhing, M.R., et al. Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat. J Pediatr Gastroenterol Nutr 32 (2001), 270–273.
130. Jacob, M., Foster, R., Sigthorsson, G., et al. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol 81 (2007), 291–298.
131. Seitz, S., Boelsterli, U.A., Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115 (1998), 1476–1482.
132. Boelsterli, U.A., Ramirez-Alcantara, V., NSAID acyl glucuronides and enteropathy. Curr Drug Metab 12 (2011), 245–252.
133. LoGuidice, A., Wallace, B.D., Bendel, L., et al. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 341 (2012), 447–454.
134. Saitta, K.S., Zhang, C., Lee, K.K., et al. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 44 (2014), 28–35.
135. Wallace, J.L., Syer, S., Denou, E., et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141 (2011), 1314–1322.
136. Schneider, H.T., Nuernberg, B., Dietzel, K., et al. Biliary elimination of non-steroidal anti-inflammatory drugs in patients. Br J Clin Pharmacol 29 (1990), 127–131.
137. Tibble, J., Sigthorsson, G., Foster, R., et al. Faecal calprotectin: a simple method for the diagnosis of NSAID-induced enteropathy. Gut 45 (1999), 362–366.
138. Brune, K., Dietzel, K., Nurnberg, B., et al. Recent insight into the mechanism of gastroinestinal tract ulceration. Scand J Rheumatol 9:Suppl 65 (1987), 135–140.
139. Ishihara, Y., Okabe, S., Effects of cholestyramine and synthetic hydrotalcite on acute gastric or intestinal lesion formation in rats and dogs. Dig Dis Sci 26 (1981), 553–560.
140. Kent, T.H., Cardeli, R.M., Stanler, F.U., Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 54 (1969), 237–245.
141. Basivireddy, J., Jacob, M., Ramamoorthy, P., et al. Alterations in the intestinal glycocalyx and bacterial flora in response to oral indomethacin. Int J Biochem Cell Biol 37 (2005), 2321–2332.
142. Watanabe, T., Higuchi, K., Kobata, A., et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57 (2008), 181–187.
143. Scarpignato, C., NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?. Gut 57 (2008), 145–148.
144. Wallace, J.L., Kennan, C.M., Granger, D.N., Gastric ulceration induced by nonsteroidal antiinflammatory drugs is a neutrophil dependent process. Am J Physiol 259 (1990), G462–G467.
145. Scarpignato, C., Dolak, W., Lanas, A., et al. Rifaximin reduces number and severity of intestinal lesions associated with use of non-steroidal anti-inflammatory drugs in humans. Gastroenterology 152 (2017), 980–982.e3.
146. Bjarnason, I., Hayllar, J., Smethurst, P., et al. Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut 33 (1992), 1204–1208.
147. Montalto, M., Gallo, A., Curigliano, V., et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy—a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 32 (2010), 209–214.
148. Endo, H., Higurashi, T., Hosono, K., et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 46 (2011), 894–905.
149. Sigthorsson, G., Tibble, J., Hayllar, J., et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 43 (1998), 506–511.
150. Moore, A., Bjarnason, I., Cryer, B., et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 7 (2009), 1156–1163.
151. Bjarnason, I., Zanelli, G., Prouse, P., et al. Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet 2 (1987), 711–714.
152. Chan, F.K., Lanas, A., Scheiman, J., et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376 (2010), 173–179.
153. Allison, M.C., Howatson, A.G., Torrance, C.J., et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 327 (1992), 749–754.
154. Somasundaram, S., Sigthorsson, G., Price, A.B., et al. The relative importance of inhibition of cyclooxygenase and uncoupling of oxidative phosphorylation in the gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 14 (2000), 639–650.